FinVolution Group Reports Third Quarter 2024 Unaudited Financial Results

-Third Quarter Total Transaction Volume reached RMB52.2 billion, up 1.8% year-over-year–Third Quarter…

TONY BUZBEE SUED FOR EXTORTION

LOS ANGELES, Nov. 19, 2024 /PRNewswire/ — Quinn Emanuel filed a lawsuit…

Canada Releases its 2024 New Wheat Crop Report

Exports of high-quality wheat expected to top 25 million tonnes this year.…

Tuya Reports Third Quarter 2024 Unaudited Financial Results

SANTA CLARA, Calif., Nov. 19, 2024 /PRNewswire/ — Tuya Inc. ("Tuya" or…

Achyuta Samanta Honoured With FIVB Grand Cross Award

BHUBANESWAR, India, Nov. 19, 2024 /PRNewswire/ — The Founder of KIIT and…

Supermicro Delivers Direct-Liquid-Optimized NVIDIA Blackwell Solutions

Supermicro’s SuperClusters with NVIDIA HGXTM B200 8-GPU, NVIDIA GB200, NVL4, and NVL72…

BLUETTI and UN-Habitat Forge Partnership to Promote Clean Energy and Sustainable Development Across Africa

LAS VEGAS, Nov. 19, 2024 /PRNewswire/ — BLUETTI, a global leader in…

Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Convergence 2024

78-Week results from Phase III randomized controlled trial (RCT) including switching data…